Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00400803
Status:
COMPLETED
Last Update Posted:
2017-12-28
First Post:
2006-11-15
Brief Title:
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIbIV Non-small Cell Lung Cancer
Sponsor:
Masonic Cancer Center University of Minnesota
Organization:
Masonic Cancer Center University of Minnesota
Organization Data
Organization:
Masonic Cancer Center University of Minnesota
Class:
OTHER
Study ID:
2007UC021
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Masonic Cancer Center University of Minnesota
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |
| Eli Lilly and Company | INDUSTRY |